Opus Point Partners Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Opus Point Partners Management’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,891	Closed	-$88K	–	51
2018 Q2	$88K	Hold	10,891	–	–	0.19%	48
2018 Q1	$81K	Sell	10,891 -10,891	-50%	-$72.4K	0.16%	50
2017 Q4	$130K	Hold	21,782	–	–	0.11%	64
2017 Q3	$160K	Hold	21,782	–	–	0.14%	63
2017 Q2	$148K	Sell	21,782 -21,783	-50%	-$161K	0.14%	66
2017 Q1	$411K	Buy	+43,565	New	+$435K	0.31%	46

Other funds holding PGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Opus Point Partners Management's PGNX Position: Q3 2018 in Review

Opus Point Partners Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2018, closing a stake of 10,891 shares — an estimated $88K sold.

Opus Point Partners Management first reported a position in PGNX in Q1 2017 and held it in 6 quarters. The position peaked at $411K in Q1 2017. 148 funds tracked by Wall St. Rank hold PGNX as of Q3 2018.

Opus Point Partners Management reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
Opus Point Partners Management sold 10,891 Progenics Pharmaceuticals Inc shares in Q3 2018, an estimated $88K.
Opus Point Partners Management first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 6 quarters.
Opus Point Partners Management's Progenics Pharmaceuticals Inc position peaked at $411K in Q1 2017.
148 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2018.

Based on Opus Point Partners Management's 13F filing for Q3 2018, filed 14 Nov 2018.